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Abstract
Background: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common
cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency
(EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective
trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these
CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for
the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME.
Expert opinion: To debate newly available CVOT data and to put them into context, we convened as a group of
medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the
conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered
alongside real-world evidence.
Conclusion: CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have
been confirmed in real-world evidence studies.
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Background
The majority of people worldwide who are living with
diabetes are affected by type 2 diabetes (T2D) [1, 2] and,
among these individuals, more than 50% of mortality is
due to cardiovascular (CV) causes [3]. Estimates of 6 or
12 fewer years of life for a typical 60-year old male with
T2D or with T2D and CV disease (CVD) have been
given when compared with counterparts in the non-
diabetic population [4]. Furthermore, the presence of
T2D confers a 2- to 5-fold higher risk of developing
heart failure (HF) and a 60–80% greater probability of
death from CV causes in those who have established HF
[5–8]. As with CVD, kidney disease is a strong predictor
of mortality in people with T2D [9], and up to 40% of
people with T2D will eventually develop kidney failure
[10]. Both low estimated glomerular filtration rate
(eGFR) and high urine albumin-to-creatinine ratio
(UACR) are independent predictors of CV death [11].
Thus, the morbidity and mortality burdens presented by
CV and renal complications of T2D are considerable.
Although lifestyle interventions are a key first step in
managing the care of people with T2D, the majority of
patients will eventually need medication [12]. Before the
late 1950s, when biguanides were introduced, only insulin
and sulfonylureas were available, but from the 1980s
onwards metformin quickly became the glucose-lowering
drug of choice for people with T2D [13]. Indeed, unless a
specific contraindication such as severe renal or liver dis-
ease is present, metformin remains the first-line drug for
the treatment of people with T2D [13]. Although three new
classes of T2D agents were introduced in the 1990s (α-glu-
cosidase inhibitors, meglitinides and thiazolidinediones), it
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was not until the turn of the Twenty-First Century that the
so-called “newer T2D agents” were introduced: dipeptidyl
peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1
(GLP-1) receptor agonists and sodium–glucose transporter
2 (SGLT2) inhibitors [13].
In recent years, the Federal Drug Administration
(FDA) has mandated CV outcomes trials (CVOTs) to
assess the CV safety of all new glucose-lowering drugs,
while the European Medicines Agency (EMA) has rec-
ommended either a CVOT or a meta-analysis [14, 15].
Unexpectedly, the results reported for treatment with
the SGLT2 inhibitor empagliflozin in the EMPA-REG
OUTCOME CVOT showed, for the first time, that an
anti-diabetic agent could not only deliver glucose-
lowering efficacy without any additional CV risk, but
could actually provide CV benefit [16]. This benefit
included a reduction in CV death in the study popula-
tion, which also contributed to a reduced risk of death
by any cause [16]. Subsequent CVOTs have also revealed
CV benefits for a small number of other glucose-
lowering drugs, whereas others did not show any CV
benefits [16–26]. Among CV benefits, only SGLT2 in-
hibitors have suggested a decrease in hospitalisation for
heart failure [6, 16–18].
With the new CVOT results, a paradigm for anti-
diabetic drugs is emerging in which glucose-lowering is
only one element of the overall treatment aim. As CV risk
is the aspect of T2D that leads to the greatest mortality
[3], we believe that CV health is an important consider-
ation when deciding on the most appropriate therapies for
any one individual. An integrated approach to disease
management is desirable, encompassing prevention or
control of CV risk together with the avoidance of renal
complications, as these two factors are inextricably linked
[27]. Furthermore, drug dosing can be challenging for
patients who develop chronic kidney disease (CKD), as
impaired kidney function can potentially influence the
pharmacokinetics of every therapeutic agent, and through
different mechanisms [28]. Given that many glucose-
lowering drugs have not yet been extensively tested in a
CKD population, making detailed analyses of renal data in
the CVOT studies could be especially important, although
dedicated renal studies are also ongoing.
At the American Diabetes Association (ADA) annual
congress in June 2017, several new sets of data were
presented from studies of SGLT2 inhibitors, including
the main results from the CANVAS Program on canagli-
flozin and the CVD-REAL real-world evidence (RWE)
study encompassing empagliflozin, canagliflozin and
dapagliflozin [17, 29]. As a group of experts in the field
from the Central and Eastern European Region, we
subsequently met to discuss the significance of the
results and to put them into context for practitioners
treating people with T2D. We here report the resultant
discussions on how best to interpret EMPA-REG OUT-
COME, the CANVAS Program and RWE in order to
inform clinical practice. During the preparation of this
manuscript, important disclosures were made regarding
the results of DECLARE-TIMI 58 (a CVOT on dapagli-
flozin) and regarding early results of the EMPRISE real-
world evidence study on empagliflozin [18, 30]; owing to
their importance for understanding the broader picture
of SGLT2 inhibitor CVOTs, these new disclosures are
also briefly discussed.
Expert opinion
SGLT2 inhibitors
SGLT2 inhibitors partially block the reabsorption of
glucose in the proximal tubules in the kidney [31]. The
members of this class have somewhat similar molecular
structure but nevertheless possess differing relative
selectivity for SGLT2 compared with SGLT1 [32]. Until
recently, three SGLT2 inhibitors had been approved by
the EMA and FDA for the treatment of T2D, as an
adjunct to diet and exercise: canagliflozin (approval:
EMA/FDA 2013); dapagliflozin (approval: EMA 2012/
FDA 2014); and empagliflozin (approval: EMA/FDA
2014). Of these three, empagliflozin shows the highest
relative selectivity, being more than 2500-fold more
selective for SGLT2 than SGLT1, followed by dapagliflo-
zin at > 1100-fold, and canagliflozin at > 250-fold [32].
Such factors may be pertinent when discussing relative
efficacies and safety profiles of these molecules, although
the clinical relevance is unknown.
At the present time, CVOTs have been reported for
empagliflozin (EMPA-REG OUTCOME), canagliflozin
(the CANVAS Program) and dapagliflozin (DECLARE-
TIMI 58) (Table 1). An additional SGLT2 inhibitor, ertu-
gliflozin, was approved by the EMA and FDA in 2018
and 2017, respectively; however, results have not yet
been reported for the ongoing ertugliflozin CVOT (VER-
TIS-CV) (Table 1).
EMPA-REG OUTCOME
The EMPA-REG OUTCOME CVOT investigated empa-
gliflozin in addition to standard of care in a population
of 7200 adult patients with both T2D and established
CVD at baseline, defined as one or more of previous
myocardial infarction (MI), stroke or unstable angina;
multivessel coronary artery disease (CAD); single-vessel
CAD if in addition to positive stress ischaemia test or
recent hospitalisation for unstable angina; or occlusive
peripheral artery disease (PAD) [16]. As the study
drug or placebo was added to standard of care, pa-
tients in all study arms were well treated for dyslipi-
daemia and hypertension [16].
The primary composite outcome was time to first oc-
currence of 3-point major adverse CV event (3P-MACE;
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that is, CV death, non-fatal stroke or non-fatal myocar-
dial infarction). Although EMPA-REG OUTCOME
was only designed to test non-inferiority for this out-
come, the study unexpectedly also demonstrated super-
iority, with a relative risk reduction (RRR) of 14%,
primarily driven by a 38% reduction in CV death [16].
Thus, key outcomes in EMPA-REG OUTCOME were
significantly improved when empagliflozin was added to
standard of care (Table 2).
Several secondary CV outcomes also showed reduc-
tions, including hospitalisation for HF (HHF) by 35%
[16]. Death by any cause showed a 32% reduction, and
the number needed to treat (NNT) to prevent one death
over three years of the study was calculated as 39 [16].
However, no significant differences to placebo were seen
for non-fatal stroke or non-fatal MI [16].
Empagliflozin in subjects at increased CV risk
It is important to consider which individuals with T2D
will benefit from empagliflozin, although, in our opinion,
it might be more appropriate simply to exclude those
who would not benefit, as empagliflozin is currently
somewhat unique in its safety and efficacy profile. We
believe that empagliflozin is increasingly perceived as
fulfilling a dual role of treating both hyperglycaemia and
CV risk factors and is therefore suitable for patients with
both T2D and CVD; indeed, this has now been recog-
nised in updated product labels and international guide-
lines [36–41]. Although the EMPA-REG OUTCOME
study included patients with established CVD, a meta-
analysis of eight randomised controlled trials (RCTs) of
empagliflozin analysed data from 11,292 subjects, in-
cluding those at low and medium, as well as high, risk of
CV events [42]. The primary endpoint was a composite
of CV death, non-fatal MI, non-fatal stroke and hospital-
isation for unstable angina (4P-MACE), and there was a
secondary endpoint of 3P-MACE [42]. 4P-MACE oc-
curred in 365 (9.5%) patients receiving placebo and 635
(8.5%) patients receiving empagliflozin (HR 0.86; 95% CI
0.76–0.98). 3P-MACE occurred in 307 (8.0%) patients
receiving placebo and 522 (7.0%) patients receiving
empagliflozin (HR 0.84; 95% CI 0.73–0.96) [42]. It can
be inferred from these data that empagliflozin remains
associated with a reduced risk of CV morbidity and mor-
tality in patients with T2D, even when those at low/
medium CV risk are included in the analysed population.
Table 1 Overview of SGLT2 inhibitor CVOTs
Study Trial # Completion Primary outcome(s) Main reported secondary CV and renal outcomes
EMPA-REG
OUTCOME
(empagliflozin)
[16, 33]
NCT01131676 Completed
2015; results
published
Time to first
occurrence of 3P-
MACE
4P-MACE; CV death; death by any cause; symptomatic MI;
symptomatic non-fatal MI; silent MI; hospitalisation for unstable an-
gina; coronary revascularisation procedure; stroke; non-fatal stroke;
TIA; HHF; HHF or CV death excluding stroke; incident or worsening
nephropathy or CV death; incident or worsening nephropathy; pro-
gression to macroalbuminuria; dSCr and eGFR ≤45ml/min/1.73m2;
initiation of RRT; dSCr and eGFR ≤45 ml/min/1.73m2, initiation of
RRT or renal death; incident albuminuria in patients with normal al-
bumin at baseline
CANVAS
Program
(canagliflozin)
[17, 34]
NCT01032629 (CANVAS)
& NCT01989754
(CANVAS-R)
Completed
2017; results
published
Time to first
occurrence of 3P-
MACE
Death by any cause; CV death; progression of albuminuria; CV
death or HHF; non-fatal MI; non-fatal stroke; MI; stroke; hospitalisa-
tion for any cause; HHF; new-onset albuminuria; new-onset microal-
buminuria; new-onset macroalbuminuria; dSCr, ESRD or renal death;
dSCr, ESRD, renal death or new-onset macroalbuminuria; dSCr,
ESRD, renal death or CV death; ≥40% decrease in eGFR, ESRD or
renal death; ≥40% decrease in eGFR, ESRD, renal death or new-
onset macroalbuminuria; ≥40% decrease in eGFR, ESRD, renal death
or CV death; 40% reduction in eGFR; dSCr; ESRD; ESRD or renal
death
DECLARE-TIMI
58
(dapagliflozin)
[18]
NCT01730534 Completed
2018; results
published
Time to first
occurrence of 3P-
MACE
Time to first
occurrence of CV
death or HHF
≥40% decrease in eGFR to eGFR < 60ml/min/1.73m2, ESRD, renal
death or CV death; death by any cause; ≥40% decrease in eGFR to
eGFR < 60 ml/min/1.73m2, ESRD or renal death; HHF; MI; ischaemic
stroke; CV death; non-CV death
VERTIS-CV
(ertugliflozin)
[35]
NCT01986881 Estimated
completion
2019
Time to first
occurrence of 3P-
MACE
Results not yet reported
Definitions differed between trials. 3P-MACE is a composite of CV death, MI and stroke. 4P-MACE is a composite of CV death, MI, stroke and hospitalisation for
unstable angina. Study names: EMPA-REG OUTCOME [cardiovascular outcomes trial of empagliflozin]; CANVAS, Canagliflozin Cardiovascular Assessment Study;
CANVAS-R, Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM; DECLARE-TIMI, Multicenter Trial to Evaluate the Effect of
Dapagliflozin on the Incidence of Cardiovascular Events; VERTIS-CV Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular
Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease. 3/4P-MACE,
3/4-point major adverse CV event; CV, cardiovascular; dSCr, doubling of serum creatinine; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease;
HHF, hospitalisation for heart failure; MI, myocardial infarction; RRT, renal replacement therapy; TIA, transient ischaemic attack
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An analysis of HHF outcomes (a prespecified sec-
ondary endpoint) in EMPA-REG OUTCOME showed
that the benefits of empagliflozin were consistent in
subjects both with and without baseline HF, i.e. pri-
mary prevention in those with no HF at baseline and
secondary prevention in those for whom HF had been
reported at baseline. The analysis showed that 1.8% of
patients receiving empagliflozin without HF at base-
line experienced an event compared with 3.1% for
placebo (HR 0.6; 95% CI 0.43–0.82); for patients with
baseline HF, the HHF figures were 10.4 and 12.3%,
respectively (HR 0.75; 95% CI 0.48–1.19) [16, 43].
The evidence for primary prevention of HF with
empagliflozin has now been recognised by new
American Heart Association (AHA) and American
College of Cardiology (ACC) guidelines [40], and on-
going clinical studies are seeking to shed more light
on this potential benefit; however, it should be noted
that empagliflozin is not currently indicated for the
treatment of HF.
Reductions in CV death were similar in patients
with and without HF at baseline: CV death events
occurred in 3.2% of subjects treated with empagliflo-
zin vs 5.3% with placebo (HR 0.60; 95% CI 0.47–
0.77) for no baseline HF, and 8.2% vs 11.1% (HR
0.71; 95% CI 0.43–1.16) for subjects with baseline
HF [43]. We note that EMPRISE will examine CV
death outcomes in a broad CV risk population in
routine clinical practice, but these data have not yet
been reported [30].
Table 2 Key efficacy outcomes in SGLT2 inhibitor CVOTs
EMPA-REG OUTCOME [16, 33] CANVAS Program [17, 34] DECLARE-TIMI 58 [18]
Placebo
(N = 2333)
Empagliflozin
(N = 4687)
Placebo
(N = 4347)
Canagliflozin
(N = 5795)
Placebo
(N = 8578)
Dapagliflozin
(N = 8582)
3P-MACE (CV death, MI or stroke)
Rate per 1000 pt-yrs 43.9 37.4 31.5 26.9 24.2 22.6
HR (95% CI; p-value) 0.86 (0.74–0.99; p = 0.04) 0.86 (0.75–0.97; p = 0.02) 0.93 (0.84–1.03; p = 0.17)
RRR (ARR) 14% (6.5 events/1000 pt-ys) 14% (4.6 events/1000 pt-yrs) N/A
CV death
Rate per 1000 pt-yrs 20.2 12.4 12.8 11.6 7.1 7.0
HR (95% CI; p-value) 0.62 (0.49–0.77; p < 0.001) 0.87 (0.72–1.06)† 0.98 (0.82–1.17)†
RRR (ARR) 38% (7.8 events/1000 pt-yrs) N/A N/A
Death by any cause
Rate per 1000 pt-yrs 28.6 19.4 19.5 17.3 16.4 15.1
HR (95% CI; p-value) 0.68 (0.57–0.82; p < 0.001) 0.87 (0.74–1.01; p = 0.24) 0.93 (0.82–1.04)†
RRR (ARR) 32% (9.2 events/1000 pt-yrs) N/A N/A
HHF
Rate per 1000 pt-yrs 14.5 9.4 8.7 5.5 8.5 6.2
HR (95% CI; p-value) 0.65 (0.50–0.85; p = 0.002) 0.67 (0.52–0.87)† 0.73 (0.61–0.88)†
RRR (ARR) 35% (5.1 events/1000 pt-yrs) 33% (3.2 events/1000 pt-yrs) 27% (2.3 events/1000 pt-yrs)
Renal composite (renal function decline*, ESRD or renal death)
Rate per 1000 pt-yrs 11.5 6.3 9.0 5.5 7.0 3.7
HR (95% CI; p-value) 0.54 (0.40–0.75; p < 0.001)† 0.60 (0.47–0.77)† 0.53 (0.43–0.66)†
RRR (ARR) 46% (5.2 events/1000 pt-yrs) 40% (3.5 events/1000 pt-yrs) 47% (3.3 events/1000 pt-yrs)
Alternative renal composite (progression to macroalbuminuria, dSCr, ESRD or renal death)
Rate per 1000 pt-yrs 76.0 47.8 27.4 15.1 Not reported
HR (95% CI; p-value) 0.61 (0.53–0.70; p < 0.001) 0.58 (0.50–0.67)†
RRR (ARR) 39% (28.2 events/1000 pt-yrs) 42% (12.3 events/1000 pt-yrs)
Please note that direct comparison of trials may not be accurate owing to differences in study design, populations and methodology. RRR and ARR are only
shown where a significant reduction was reported, or a nominally significant reduction in the case of an exploratory analysis. *Defined as: dSCr accompanied by
eGFR of < 45 ml/min/1.73 m2 in EMPA-REG OUTCOME; ≤40% decrease in eGFR in the CANVAS Program; and ≤ 40% decrease in eGFR to < 60 ml/min/1.73 m2 in
DECLARE-TIMI 58. †Exploratory analysis, p-value is nominal or not available. 3P-MACE, 3-point major adverse CV event; ARR, absolute risk reduction; CI, confidence
interval; CV, cardiovascular; dSCr, doubling of serum creatinine; HHF, hospitalisation for heart failure; HR, hazard ratio; MI, myocardial infarction; pt-yrs, patient-
years; RRR, relative risk reduction
Schernthaner et al. BMC Endocrine Disorders           (2019) 19:64 Page 4 of 13
Renal outcomes in EMPA-REG OUTCOME
The population of EMPA-REG OUTCOME included a
substantial renal burden, with eGFR < 60 mL/min/
1.73m2 in 26% of patients and 60–< 90mL/min/1.73m2
in 52% of patients [16, 33]. The main pre-specified renal
composite outcome of new or worsening nephropathy
(progression to macroalbuminuria, doubling of the
serum creatinine level, initiation of renal-replacement
therapy, or death from renal disease) was significantly
reduced by 39%, and doubling of serum creatinine with
an eGFR ≤45mL/min/1.73m2 was reduced by 44% when
adding empagliflozin to standard of care [16, 33].
Significant benefits were also seen in several other pre-
specified renal parameters, including a 32% RRR in new
or worsening nephropathy or CV death (p < 0.001); 38%
RRR in progression to macroalbuminuria (p < 0.001);
and 55% RRR in initiation of renal replacement therapy
(p = 0.04) [33]. The only exception was incident albu-
minuria in patients with a normal albumin level at base-
line, where no significant difference between study arms
was observed [33].
The renal results in EMPA-REG OUTCOME indicate
that empagliflozin delays the progression of renal disease
when compared with placebo [33]. The change in eGFR
over time also supports a nephroprotective effect: after
an initial fall when empagliflozin therapy was started,
the eGFR of subjects on empagliflozin recovered some-
what and subsequently remained stable, whereas those
on placebo demonstrated a steady decline over the
period of the study [33]. Furthermore, a post hoc
analysis showed that the renal benefits seen with
empagliflozin in the full study cohort were consistent in
a subgroup of patients with prevalent kidney disease at
baseline, defined as having an eGFR < 60mL/min/1.73m2
and/or macroalbuminuria (UACR > 300mg/g) [44].
Despite the promising renal results, it should be noted
that EMPA-REG OUTCOME was a CV trial with 3P-
MACE as the primary endpoint, and therefore we await
the results of an ongoing dedicated renal study before
making a more conclusive assessment of empagliflozin
in this setting. Furthermore, in accordance with local
prescribing information and licences for SGLT2 inhibi-
tors, if the eGFR is below 60 mL/min/1.73 m2 then
empagliflozin should not be initiated and must be dis-
continued if the eGFR persistently falls below 45ml/
min/1.73 m2 [36].
Key safety data in EMPA-REG OUTCOME
Of note, the only adverse event for which an increased
incidence was associated with empagliflozin in EMPA-
REG OUTCOME was the occurrence of genital infec-
tions (overall, 6.4% vs 1.8%; p < 0.001), and these are eas-
ily treatable [16]. In contrast to the recent data from the
CANVAS Program (see below; Table 3), [17] there was
no significant increase with empagliflozin on the risk of
bone fracture or lower limb amputation [16, 45], includ-
ing in patients with PAD [47].
The CANVAS Program
The CANVAS Program is a pooled analysis of two
subsidiary studies: CANVAS, a CV safety study, and
CANVAS-Renal (CANVAS-R), which included
Table 3 Key safety outcomes in SGLT2 inhibitor CVOTs
EMPA-REG OUTCOME [45, 46]* CANVAS [17, 46] CANVAS-R [17, 46] DECLARE-TIMI 58†
[18, 46]
Placebo
(N = 2333)
Empa 10
(N = 2345)
Empa 25
(N = 2342)
Placebo
(N = 1441)
Cana 100
(N = 1445)
Cana 300
(N = 1441)
Placebo
(N = 2903)
Cana 100
(N = 2904)
Placebo
(N = 8569)
Dapagliflozin
(N = 8574)
Patients with lower limb amputation
n (%) 43 (1.8) 42 (1.8) 46 (2.0) 22 (1.5) 50 (3.5) 45 (3.1) 25 (0.9) 45 (1.5) 113 (1.3) 123 (1.4)
Events per 1000
patient-years
6.5 6.2 6.8 2.8 6.2 5.5 4.2 7.5 3.3 3.6
Hazard ratio (95% CI) – 0.96
(0.63–1.47)
1.04
(0.69–1.58)
– 2.24
(1.36–3.69)
2.01
(1.20–3.34)
– 1.80
(1.10–2.93)
– 1.09
(0.84–1.40)
Diabetic ketoacidosis
Placebo
(N = 2333)
Empagliflozin (pooled)
(N = 4687)
Placebo (pooled‡)
(N = 4347)
Canagliflozin (pooled‡)
(N = 5795)
Placebo
(N = 8569)
Dapagliflozin
(N = 8574)
n (%) 1 (< 0.1%) 4 (0.1%) 6 12 12 27
Events per 1000
patient-years
< 0.1 0.1 0.3 0.6 0.4 0.9
Hazard ratio (95% CI) – 1.99 (0.22–17.80) – 2.33 (1.10–7.17) – 2.18
(1.10–4.30)
These trials cannot be directly compared, owing to differences in study design, populations and methodology. *Post hoc analysis for lower limb amputation,
which was not a prespecified outcome in EMPA-REG OUTCOME. †All amputation; data for lower limb amputation not provided. ‡Diabetic ketoacidosis events
pooled across CANVAS and CANVAS-R, and 100mg and 300 mg doses of canagliflozin. Pooled cohort size indicates the intention to treat population. Cana 100/
300, canagliflozin 100/300 mg; Empa 10/25, empagliflozin 10/25 mg
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albuminuria progression as a key outcome alongside CV
safety outcomes [17].
The CANVAS Program study design
The CANVAS CVOT was a randomised controlled trial
designed to assess the CV safety of canagliflozin versus
placebo, on top of standard of care in 4330 patients with
T2D and either symptomatic CVD (one or more of
CAD, cerebrovascular disease or PAD) or multiple CV
risk factors (age ≥ 50 and two or more of dyslipidaemia,
hypertension, current smoker, ≥10 years diabetes
duration, or albuminuria) at baseline [17]. A public
disclosure of interim analyses was required for regula-
tory filings, and plans to further assess CV protection
through an expansion of the study were terminated at
that time [17, 48, 49]. Instead, in order to achieve suffi-
cient power for CV assessment, the additional
CANVAS-R CVOT (N = 5813) was combined with
CANVAS into the CANVAS Program, enabling a pooled
analysis, but excluding events accrued prior to 20
November 2012, which was the date of last unblinding
[17, 48, 49]. CANVAS-R was a shorter study, with
median follow-up 2.1 years [17].
Statistical analyses were performed as a sequential
hypothesis testing plan of the pooled data from CAN-
VAS and CANVAS-R to give a total of 5795 individuals
treated with canagliflozin and 4347 placebo controls
[17]. As with EMPA-REG OUTCOME, the primary end-
point in the CANVAS Program was time to first
occurrence of 3P-MACE (first testing for non-inferiority
and then superiority) [17]. Next was a test for superiority
for death by any cause, followed by superiority for CV
death [17]. Once a non-significant result was encoun-
tered, subsequent analyses were exploratory only.
Key outcomes in the CANVAS Program
The primary analysis yielded a positive result, with 26.9
participants receiving canagliflozin experiencing an
event per 1000 patient-years compared with 31.5 in the
placebo group (HR 0.86; 95% CI 0.75–0.97, p = 0.02 for
superiority); however, superiority was not shown for the
first secondary outcome (death by any cause, HR 0.87
95% CI 0.74–1.01), so the sequential hypothesis testing
ended there [17]. This means that the results of all
subsequent secondary analyses could not be considered
as significant but rather as exploratory analyses (Table 2)
[17].
It should be noted here that superiority for death
by any cause and CV death were additions made by
the independent trial steering committee for the
CANVAS Program when revising the original analysis
plan [48, 49]. These revisions were made in the
expectation that the results for individual mortality
outcomes would be stronger than for the composite
outcome of 3P-MACE, as had been seen in EMPA-REG
OUTCOME [48, 49]. Adding CV death as an outcome
also presented an opportunity to demonstrate superiority
in an individual CV outcome [48, 49]. However, the lack
of superiority for all-cause mortality in the pooled data
means that the subsequent analysis of CV death was
exploratory only [17]. Similarly, subsequent analysis of
CANVAS-R data alone, including superiority for albumin-
uria progression, composite of HHF and CV death, and
CV death, also remain exploratory only [17].
Canagliflozin in subjects at increased CV risk
The significant 3P-MACE finding echoes that in EMPA-
REG OUTCOME for empagliflozin; however, the lack of
significance for both CV death and death by any cause
was disappointing from a clinical point of view, as these
parameters may be of most interest to clinicians, given
the prevalent CV risk in patients with T2D [17].
The CANVAS Program study populations comprised
58.9% of patients with symptomatic CVD in CANVAS
and 70.7% in CANVAS-R; the pooled figure was 65.6%
[17]. These figures for CV involvement are more hetero-
geneous than the EMPA-REG OUTCOME population,
where 99% of participants had established CVD [16].
Analysis of risk groups has shown that canagliflozin was
superior to placebo for 3P-MACE in the secondary pre-
vention group only, with no difference from placebo
when looking only at primary prevention [46, 50]. How-
ever, when analysed for interactions between the pri-
mary, secondary and overall population, no statistically
significant difference was seen (p = 0.18) [50].
The 35% of CANVAS Program patients who had CV
risk factors but not symptomatic disease represent a
challenge when interpreting the results, as the absence
of symptoms does not necessarily represent an absence
of disease, as evidenced by studies showing that people
with T2D are known to have a high burden of asymp-
tomatic CVD and that CAD may manifest in a silent
fashion [51].
Renal outcomes in the CANVAS program
Analyses of renal outcomes in the CANVAS Program
were exploratory only, owing to the failure to meet
previous endpoints in the statistical hierarchy [17].
Nevertheless, exploratory findings with canagliflozin
were promising, suggesting reductions not only in albu-
minuria, which we believe may not be the most robust
metric for assessing effect on kidney function, but also
in doubling of serum creatinine, which is a key marker
of impaired renal function [34]. These suggested benefits
are consistent with renal observations with empagliflozin
treatment in EMPA-REG OUTCOME [33]. Renal bur-
den in the CANVAS Program population was also rem-
iniscent of EMPA-REG OUTCOME, with eGFR < 60
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mL/min/1.73m2 in 20% of patients and 60–< 90mL/
min/1.73m2 in 55% of patients [52].
Key safety data from the CANVAS program
The safety results of note from the CANVAS Program
showed an approximate two-fold increased risk of lower
limb amputations with canagliflozin versus placebo (6.3
vs. 3.4 participants with amputation per 1000 patient-
years: HR 1.97; 95% CI 1.41–2.75, p < 0.001) (Table 3),
and confirmed a previous suggested increase in bone
fractures (15.4 vs 11.9 participants with fracture per
1000 patient-years; HR, 1.26; 95% CI 1.04 to 1.52, p =
0.02) [17]. The only other event of significance in the
CANVAS Program was an increase in genital infections
in both men and women (p < 0.001), most likely due to
the increased levels of glucose in the urine, and also seen
with other SGLT2 inhibitors [17].
The incidence of lower limb amputation with canagliflo-
zin was not uniform across all groups: patients with ath-
erosclerosis and previous amputation had a higher risk of
amputation compared with other patients [17]. Although
amputations of the toe and middle of the foot were the
most common, amputations involving the leg, below and
above the knee, also occurred and some patients had more
than one amputation, some involving both limbs [17].
In February 2017, the EMA issued a statement requiring
a warning of the potential increased risk of toe amputation
in the prescribing information for all SGLT2 inhibitors
based on canagliflozin data, including from the CANVAS
Program; however, the statement noted that an increased
risk has not been seen to date in studies with empagliflo-
zin or dapagliflozin [53]. Indeed, although amputation was
not a pre-specified safety outcome of EMPA-REG OUT-
COME, a post hoc analysis found no increased signal for
amputation with empagliflozin compared with placebo
[45]. Both the EMA and FDA have required the addition
of a warning for increased risk of lower limb amputation
to the canagliflozin label, but not to the empagliflozin or
dapagliflozin labels [54].
The mechanisms by which canagliflozin may increase
the risk of amputation are still unclear [54], especially
as, we suggest, there does not appear to be a similar sig-
nal from empagliflozin or dapagliflozin. We believe that
the increase in amputation rate is concerning, as the po-
tential repercussions on quality of life are profound. It
can be argued that many, if given the choice, would opt
to accept an increased CV risk over a doubled risk of
amputation.
DECLARE-TIMI 58
The first results for the DECLARE-TIMI 58 CVOT on
dapagliflozin have now been reported, enabling a more
comprehensive analysis of CV and renal outcomes across
the SGLT2 inhibitor class [18]. Although the data were
disclosed subsequent to our initial discussions, and dur-
ing the preparation of this manuscript, we believe that it
is important to briefly address the findings here.
Notably, DECLARE-TIMI 58 is the first CVOT in the
SGLT2 inhibitor class to include a majority of primary
prevention patients; that is, 59% of patients had multiple
CV risk factors (male aged ≥55 or female aged ≥60 with
one or more of dyslipidaemia; hypertension; or
current smoker), whereas only 41% of patients had
established atherosclerotic CVD (age ≥ 40 with one or
more of CAD; ischaemic cerebrovascular disease; or
PAD) [18, 55].
In the initial study design, the primary safety endpoint
was non-inferiority for 3P-MACE and the primary
efficacy endpoint was superiority for 3P-MACE, as with
EMPA-REG OUTCOME and the CANVAS Program.
However, following EMPA-REG OUTCOME, a new co-
primary composite efficacy endpoint of HHF and CV
death was added, with permission from regulators, in
light of the new insights that these outcomes may be
highly clinically relevant with SGLT2 inhibitors [16, 18,
56].
As expected, DECLARE-TIMI 58 demonstrated that
dapagliflozin was non-inferior to placebo as an add-on
to standard of care in the study population, thus meeting
the primary safety endpoint [18]. Similarly, DECLARE-
TIMI 58 added further evidence that a reduction in
HHF is consistent across the SGLT2 inhibitor class, as
the co-primary efficacy endpoint of HHF or CV death
was also met, and this was driven entirely by a decreased
risk of HHF, while there was no difference between
dapagliflozin and placebo in risk of CV death [18].
However, the study failed to meet the primary efficacy
endpoint of superiority for 3P-MACE, with no signifi-
cant difference between dapagliflozin and placebo [18].
Furthermore, even when looking only at patients with
baseline established atherosclerotic CVD (a similar size
cohort to EMPA-REG OUTCOME), there remained no
significant benefit in either 3P-MACE or CV death with
dapagliflozin [18, 46]. The risk of death by any cause
was also not significantly reduced with dapagliflozin vs
placebo [18].
Considering EMPA-REG OUTCOME alongside the CANVAS
Program and DECLARE-TIMI 58
Although direct comparisons can only be made between
the effects of different agents in head-to-head studies,
owing to differences in populations, trial designs, analyt-
ical approaches and drug effects, it can nevertheless be
useful for clinicians to critically appraise data in the
context of similar studies.
In a clinical setting, we believe that CV death could be
considered to be the most relevant parameter for assessing
the overall benefit from a glucose-lowering drug for
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patients with T2D, as reductions in CV death are the
prime goal of treatment. In the EMPA-REG OUTCOME
study, the RRR of CV death for empagliflozin vs placebo
was 38% (HR 0.62; 95% CI 0.49–0.77, p < 0.001) [16]. By
contrast, as described above, the RRR of CV death did not
achieve statistical significance in either the CANVAS
Program or in DECLARE-TIMI 58 [17, 18]. Thus, reduc-
tion in CV death was, among SGLT2 inhibitors, a unique
finding with empagliflozin.
The results for HHF and renal outcomes were more
similar between the three CVOTs. Whereas HHF is only
presented as an exploratory outcome in the CANVAS
Program (HR 0.67; 95% CI 0.52–0.87) and DECLARE-
TIMI 58 (HR 0.73; 95% CI 0.61–0.88), the observed
trend towards treatment benefit is similar to that seen
with empagliflozin in EMPA-REG OUTCOME, where
RRR for HHF was 35% (HR 0.65; 95% CI 0.50–0.85,
p < 0.001) [16–18].
The design of composite renal outcomes differed be-
tween studies, and there is not a composite renal end-
point that has been reported for all three CVOTs. For
the CANVAS Program, the key renal composite was a
40% reduction in eGFR, requirement for renal replace-
ment therapy, or death from renal causes [17], while in
DECLARE-TIMI 58 the composite comprised 40%
reduction in eGFR to < 60 ml/min/1.73m2, end-stage
renal disease, or death from renal causes [18]. Due to
the failure to meet earlier endpoints, these renal
outcomes were exploratory only in the two trials, but
nevertheless both suggested a strong trend towards a
protective effect with treatment, with 40% reduction in
the CANVAS Program (HR 0.60; 95% CI 0.47–0.77) and
47% reduction in DECLARE-TIMI 58 (HR 0.53; 95% CI
0.43–0.66).
There was no equivalent pre-specified endpoint in
EMPA-REG OUTCOME, although a post hoc analysis
of doubling of serum creatinine accompanied by an
eGFR of < 45ml/min/1.73 m2, initiation of renal replace-
ment therapy, or death due to renal disease is the closest
approximate, and showed a similar benefit to the other
CVOTs (46% reduction; HR 0.54; 95% CI 0.40–0.75)
(Table 2) [33]. As noted above, results for the EMPA-
REG OUTCOME prespecified composite of incident or
worsening nephropathy, which also included progression
to macroalbuminuria, were also similar (HR 0.61; 95%
CI 0.53–0.70, p < 0.001) [16, 33]. An equivalent compos-
ite in the CANVAS Program yielded similar results in an
exploratory analysis (HR 0.58; 95% CI 0.50–0.67) [34].
Albuminuria outcomes have not yet been reported for
DECLARE-TIMI 58 [18].
In safety outcomes, much attention has been paid to
the doubling of lower limb amputations in the CANVAS
Program, in contrast to DECLARE-TIMI 58 and EMPA-
REG OUTCOME, where no signal was seen (Table 3)
[17, 18, 45]. Thus, canagliflozin is to date the only
SGLT2 inhibitor that has produced a CVOT signal for
lower limb amputation risk.
Bone fracture risk was also increased in the CANVAS
Program but not EMPA-REG OUTCOME or DECLARE-
TIMI 58, whereas the rare event of diabetic ketoacidosis
(DKA) was significantly increased in DECLARE-TIMI 58
and had a trend towards an increase that did not reach
significance in the CANVAS Program and EMPA-REG
OUTCOME (Table 3) [16–18]. The prescribing informa-
tion for all SGLT2 inhibitors cautions prescribers to be
alert for signs of DKA, which although rare is potentially
dangerous and may present atypically (that is, in patients
with only moderately increased blood glucose values) [36].
There was a mixed picture for urogenital infections in
SGLT2 inhibitor CVOTs. While there was a consistent
signal for increased risk of genital infections with all three
agents, which was also seen in previous trials [16–18],
none of the CVOTs showed an increase risk of urinary
tract infection (UTI), although a signal was seen with
empagliflozin when looking at female patients alone [16].
Other studies have shown inconsistent results for UTI risk
with SGLT2 inhibitors, with four recent meta-analyses
finding no evidence for increased risk of UTI with any
agent in the class, with the possible exception of high dose
(10mg) dapagliflozin [57–60]. Nevertheless, prescribers
should be advised that current product labels contain a
warning about possible UTI events [36].
To summarise the SGLT2 CVOT data, despite the
recent CANVAS Program and DECLARE-TIMI 58
results, empagliflozin remains the only member of the
SGLT2 inhibitor class thus far having proven a
significant reduction in CV death (38% RRR) in a dedi-
cated and robust CVOT that was designed, and pow-
ered, to test for superiority in CV outcomes versus
placebo [16–18]. Furthermore, the reduced risk of CV
death with empagliflozin was consistent across pre-
specified analyses [16]. By contrast, there was no signifi-
cant reduction in CV death versus placebo with either
canagliflozin, in the CANVAS Program, or dapagliflozin,
in DECLARE-TIMI 58, and this was true whether ana-
lysing each study population as a whole or only the
patients with baseline symptomatic atherosclerotic CVD
[17, 18, 46, 50]. However, HHF and renal endpoints sug-
gested that all SGLT2 inhibitors provided a benefit for
these outcomes, although these analyses were explora-
tory only in the CANVAS Program and DECLARE-
TIMI 58 due to the hierarchical statistical testing plan
design [16–18, 33, 34]. Safety outcomes also showed dif-
ferences, with increased risk of lower limb amputation
and bone fracture in the CANVAS Program, but not
EMPA-REG OUTCOME or DECLARE-TIMI 58, al-
though an increased risk of genital infections was con-
sistent across the class, and prescribers should be
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advised of the possibility of rare DKA events with all
three agents [16–18, 36, 45].
One possible explanation for different outcomes be-
tween SGLT2 inhibitor CVOTs may be differences in
study design, some of which are outlined above. How-
ever, another explanation may be the differences in mo-
lecular structure that result in different relative
selectivity for SGLT2 over SGLT1 [32]. SGLT1 inhibition
is known to cause gastrointestinal problems and investi-
gations into the earliest SGLT2 inhibitors were aban-
doned owing to their lack of selectivity between SGLT1
and SGLT2 [61]. It may be that there are other repercus-
sions of the different molecular structures that have not
yet been identified.
Real-world evidence
In recent years, RWE has begun to provide insights into
clinical and health economic outcomes with SGLT2 in-
hibitors in routine clinical practice, and ongoing RWE
studies are set to shed still further light on this in the
years to come. RWE is captured in natural, uncontrolled
settings outside of traditional RCTs, and has been said
to “represent a measure in understanding healthcare
data collected under real-life practice circumstances”
[62]. RWE studies can provide data on effectiveness and
safety during routine care, complement and support data
from RCTs, and support market access and reimburse-
ment decisions [62]. However, RWE alone is insufficient
to demonstrate efficacy, and thus cannot be used on its
own to meet regulatory requirements for passing a new
indication or extending an existing indication [63]. RWE
is commonly used for patient profiling and prevalence,
defining treatment pathways and patterns of care, evalu-
ating compliance and persistence, determining treatment
costs and costs in disease stages and disease states, and
informing investigations on health outcomes and disease
sequelae [62].
CVD-REAL
CVD-REAL was a RWE study that compared the rate of
HHF in individuals with T2D who had been newly initi-
ated on SGLT2 inhibitors (canagliflozin, dapagliflozin or
empagliflozin) versus other glucose-lowering drugs
(oGLDs), with secondary aims of comparing the risk of
all-cause death, and HHF or all-cause death, between
the two treatment groups [29]. The cohort included both
patients with and without established CVD at baseline
[29]. For patients without CVD at baseline, HF may be a
key outcome, as it was shown to be among the most
common first presentations of CVD in a prospective co-
hort study of health records over 5.5 years (14.1% of pa-
tients with T2D) [64].
Data for CVD-REAL were gathered from registries
and national initiatives from six different countries (US,
UK and Nordic countries). From an initial post-
screening population of 160,033 people who had been
prescribed an SGLT2 inhibitor and 1,226,221 who had
been given an oGLD, subjects were propensity matched
1:1 to give a test population of 154,528 for each of
SGLT2 inhibitors or oGLDs [29]. This propensity match-
ing step ensured that the baseline characteristics were
similar for each group, although they did differ some-
what from CVOTs: for example, patients were relatively
young (57 years vs 63–64 years in CVOTs); fewer (13%)
had prior CVD; statin use was relatively high at 67%, but
slightly less than in CVOTs; and concomitant GLP-1 re-
ceptor agonists were much more widely used (18–20%
in CVD-REAL vs 3–5% in SGLT2 inhibitor CVOTs)
[16–18, 29]. Overall, 53% of the study population re-
ceived canagliflozin, 37% received dapagliflozin and 10%
received empagliflozin. These percentages varied by re-
gion: in the US, 75.9% received canagliflozin, whereas in
Europe 91.9% received dapagliflozin. All three primary
analyses favoured SGLT2 inhibitors over oGLD: HHF
(HR 0.61; 95% CI 0.51–0.73, p < 0.001); death by any
cause (HR 0.49; 95% CI 0.41–0.57, p < 0.001), and a
composite of HHF or death by any cause (HR 0.54; 95%
CI 0.48–0.60, p < 0.001) [29]. Results for individual
SGLT2 inhibitors were not reported.
The related study CVD-REAL 2 used a similar study
design to look at CV and mortality outcomes in real-
world data from an additional six countries (four from
Asia Pacific, plus Canada and Israel), with 235,000 treat-
ment initiations in each study arm [65]. In this second
study, 75% of patients received dapagliflozin, with the re-
mainder split between empagliflozin (9%), canagliflozin
(4%), and three additional SGLT2 inhibitors that are not
currently licensed in the European Union (12%) [65]. Re-
sults in CVD-REAL 2 were similar to CVD-REAL, with
a lower incidence of the composite of HHF or death by
any cause (HR 0.60; 95% CI 0.47–0.76, p < 0.001), as well
as a lower incidence of the individual components HHF
(HR 0.64; 95% CI 0.50–0.82, p = 0.001) and death by any
cause (HR 0.51; 95% CI 0.37–0.70, p < 0.001) [65].
EASEL
The EASEL study was a retrospective cohort study of
SGLT2 inhibitors in patients with T2D and CVD that
used data from the US Department of Defense (DoD)
Military Health System (MHS) [66]. The study found
that patients newly initiated on SGLT2 inhibitors had
43% fewer HHF or death by any cause events than pro-
pensity matched patients initiated on non-SGLT2 inhibi-
tor therapy (1.73 versus 3.01 composite events per 100
person-years; HR, 0.57; 95% CI, 0.50–0.65) [66]. Simi-
larly, the number of MACE events was 33% lower in the
SGLT2 inhibitor cohort than in the propensity matched
non-SGLT2 inhibitor cohort (2.31 versus 3.45 events per
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100 person-years; HR, 0.67; 95% CI, 0.60–0.75). How-
ever, pooled safety data showed that SGLT2 inhibitors
were associated with an approximately 2-fold higher risk
of below knee lower extremity amputation, similar to
the risk observed with canagliflozin in the CANVAS
Program [17, 66]. The amputation rates for the individ-
ual agents varied slightly, with canagliflozin showing a
slightly higher incidence rate than empagliflozin or
dapagliflozin, after propensity matching [66].
EMPRISE
During the preparation of this manuscript, early results
from an additional RWE study were announced. The study,
EMPRISE, uses 3 large US databases to assess outcomes
with empagliflozin in routine clinical practice, with DPP-4
inhibitors as an active comparator [30]. EMPRISE will as-
sess a range of effectiveness, safety, healthcare resource util-
isation and cost outcomes, in a patient population with a
much broader CV risk than in EMPA-REG OUTCOME
[30]. By the time of study completion, it is envisaged that
232,000 patients will have been included over the course of
5 years, with 116,000 patients in each propensity matched
arm [30]. Recently, initial effectiveness results after 5
months follow-up were disclosed for selected outcomes in
the first 35,000 patients [30]. These results suggested that
patients receiving empagliflozin had substantially fewer
HHF events than patients receiving DPP-4 inhibitors (HR
0.49; 95% CI 0.27–0.89) [30]. Thus, preliminary results
from EMPRISE are reminiscent of the rapid benefit seen
with empagliflozin in reducing HHF events in the con-
trolled conditions of EMPA-REG OUTCOME [16, 43].
RWE data in context
We believe that the value of RWE must be cautiously taken
in the context of evidence from CVOTs, as data generated
from observational studies are not comparable to gold
standard RCTs, and residual confounding such as selection
bias cannot be excluded. For example, no information is
available on the safety profile of SGLT2 inhibitors within
CVD-REAL, nor on CV risk, making it difficult to draw
conclusions regarding risk:benefit profiles. Of particular
note, the reductions in all-cause mortality reported with
pooled SGLT2 inhibitors in CVD-REAL were not replicated
for canagliflozin in the CANVAS Program, nor for dapagli-
flozin in DECLARE-TIMI 58 [17, 18, 29]. Indeed, there is a
possible inherent bias in the CVD-REAL design, due to the
hierarchical nature of therapy for T2D, in which patients
are generally prescribed SGLT2 inhibitors only after therapy
with oGLD. This means that for such patients the oGLD
treatment period becomes defined as “immortal”, as pa-
tients who are subsequently prescribed SGLT2 inhibitors,
by definition, have survived [29, 67]. However, we note that
the authors of the study have argued against the potential
of such a bias to affect the results [68], and as such the
subject remains a matter of debate [69]. Concerns over the
possibility of immortal time bias have been addressed in
the study design for EMPRISE, where patients are matched
for number of diabetes therapies and the study is designed
to compare treatments with the same position in the treat-
ment pathway [30].
It is our opinion that RWE studies can be of use where
the data support and agree with results from RCTs. For
example, the evidence from RWE supports the findings
from CVOTs showing a reduction in HHF with SGLT2 in-
hibitors, which suggests that the reduction in HHF dem-
onstrated in CVOTs may be observed in T2D patients
across a broad continuum of CVD in routine clinical
practice.
SGLT2 inhibitors and class effect — what is the evidence
from CVOTs and RWE?
Taking into consideration the various results from
SGLT2 inhibitor CVOTs, we consider that it is still too
early to safely assume a class effect. As such, we believe
that each agent should be evaluated according to its in-
dividual data and merit.
In particular, we feel that the different results in CV
death, death by any cause and safety cast doubt on the po-
tential extent of a class effect, despite similar reductions in
HHF and renal outcomes (and exploratory findings) be-
tween the three CVOTs. We note that variability across a
class in CV death outcomes has a clear precedent in
CVOTs: among GLP-1 receptor agonist CVOTs, a reduc-
tion in CV death was seen with liraglutide, but not with
lixisenatide, exenatide, semaglutide or the unlicensed
agent albiglutide [23–26, 70].
International guidelines that have been updated in the
light of CVOTs have recognised this distinction, recom-
mending an SGLT2 inhibitor or GLP-1 receptor agonist
with proven CV benefit for patients with T2D in an ath-
erosclerotic CVD setting [37–39]; or an SGLT2 inhibitor
with proven HF or CKD benefit in patients where HF or
CKD predominates [37, 38].
Conclusions
CVOTs investigating SGLT2 inhibitors have suggested
benefits beyond glucose lowering that have been con-
firmed in RWE studies [16–18, 29, 30, 33, 34, 65, 66],
which has led guidelines to support a favourable position-
ing for these agents early in the treatment pathway for pa-
tients with T2D in the setting of CV risk, HF and renal
disease [37–41]. However, empagliflozin is the only drug
within this class to have demonstrated proven efficacy and
safety across the most relevant endpoints, namely CV
death and death by any cause, as well as other CV and
renal outcomes [16–18].
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